Navigation Links
Chimerix Initiates a Multi-dose Clinical Trial of the Company's Lead Compound, CMX001, for the Treatment for Smallpox Infection
Date:12/11/2007

RESEARCH TRIANGLE PARK, N.C., Dec. 11 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the Company has initiated a multi-dose trial with its lead drug candidate, CMX001, an oral treatment for smallpox infection. This trial will study the pharmacokinetics and safety of three doses of the drug given to healthy volunteers.

"The high oral availability demonstrated by CMX001 in the Phase I trial has validated the utility of the company's lipid technology, ProLipTag(TM) and creates optimism for the potential of this drug candidate," said Dr. George Painter, Chimerix President and CEO. "In addition to smallpox, we believe that CMX001 has great potential in treating other serious infections such as human papillomavirus and cytomegalovirus."

CMX001 is being developed for the treatment of smallpox infection and other double stranded DNA virus infections that cause significant human morbidity and mortality. A safe, orally active antiviral drug for smallpox is needed to provide a means of treating people who become ill post exposure to the disease or who cannot be vaccinated. Chimerix has previously demonstrated that single doses of CMX001 provided excellent drug exposure and were well tolerated in healthy volunteers. CMX001 is being developed for smallpox under a licensing agreement with Gilead Sciences, Inc. The work is partially funded by a $36.1 million grant awarded to the company by the National Institutes of Allergy and Infectious Disease.

About Chimerix

Chimerix, Inc. discovers, develops and commercializes therapeutics with enhanced pharmaceutical properties that are active against a broad range of viral diseases. Leveraging a powerful lipid, prodrug technology, ProLipTag(TM), Chimerix is able to develop drug candidates with oral-availability, increased potency and targeted delivery. These enhanced pharmaceutical properties can be applied to new drug moieties or known drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse events.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
6. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
7. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. Prolexys Pharmaceuticals Initiates Phase 1 Study
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2017)... , June 12, 2017 Kineta, Inc., a biotechnology ... Kineta Vice President of R&D and Head of ... Pandemic Preparedness for the Northwest and Beyond meeting ... on June 14, 2017 from 8:30-10:30 AM PDT at the ... Dr. Bedard will be joined by other ...
(Date:6/9/2017)... and INDIANAPOLIS , June 9, ... living with diabetes. In a further effort to help ... affected by this condition, the International Diabetes Federation (IDF) ... ) have come together for the second phase of ... Systems programme (BRIDGES 2), reaffirming their commitment to helping ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
Breaking Medicine Technology:
(Date:6/22/2017)... ... 2017 , ... Vighter, a premier provider of Unconventional Medical ... PSC.1-2012. The company’s work in countries throughout Southwest Asia, South America, and the ... degraded. The PSC.1 standard was created to protect fundamental freedoms and human rights ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... services, announced today that Claritas Capital, a Nashville-based private equity firm, has invested ... our expansion plans for some time, and Claritas Capital offers the smart money, ...
(Date:6/20/2017)... ... June 20, 2017 , ... After months of negotiations, FaceCradle USA is proud to ... on Wednesday, June 21. , “Introducing our product on QVC is something we all worked ... our travel pillow to more than 90 million homes in the United States,” said FaceCradle ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Fresenius Vascular Care, ... minimally invasive techniques to treat and manage a wide range of vascular conditions, has ... initiative. With more than 65 centers represented by more than 40 local brands, a ...
(Date:6/20/2017)... ... June 20, 2017 , ... HOUSTON – Brazos Towers at Bayou Manor ... of new options for today’s modern senior. Brazos Towers at Bayou Manor has more ... love while offering them the services to support that lifestyle both now and in ...
Breaking Medicine News(10 mins):